NEUARTIGE ANTI-PRESEPSIN-ANTIKÖRPER

European patent · EP3628731 · In force

Register entry

Publication number
EP3628731
Application number
EP19188513
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 25, 2015
Published
Apr 1, 2020
Granted
Apr 21, 2021
Protection ends at the latest
Feb 24, 2035
Next annual fee due
Feb 28, 2027
IPC classes
C12N 15/09 (2006.01)
C07K 16/28 (2006.01)
C12N 5/10 (2006.01)
G01N 33/53 (2006.01)
Priority
US 201461944674 P 26.02.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Mar 2, 2022

    Change

    Published in Swissreg on 02.03.2022

  6. Jun 19, 2021

    Agent entered

    Representative
    BOHEST AG, Holbeinstrasse 36-38, 4051 Basel

    Published in Swissreg on 19.06.2021

  7. Apr 21, 2021

    Granted

    Published in Swissreg on 21.04.2021

Parties

Holder

Mochida Pharmaceutical Co., Ltd.

7 Yotsuya 1-chome Shinjuku-ku, Tokyo 160-8515, JP

Agent

BOHEST AG

Holbeinstrasse 36-38, 4051 Basel

Inventor

SHIRAKAWA, Kamon

Tokyo 160-8515, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.